Skip to content
lifestyle.marketresearchjournals.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals to Report Second Quarter 2026 Financial Results and Provide a Corporate Update on August 6, 2026
July 30, 2026
Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel
July 21, 2026
Verrica Pharmaceuticals Announces First U.S. Patient Dosed in the Second Pivotal Clinical Trial (COVE-3) of its Phase 3 Program Evaluating YCANTH® (VP-102) for the Treatment of Common Warts
June 22, 2026
Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference
May 28, 2026
Verrica Pharmaceuticals Appoints Chris Chapman as Chief Commercial Officer
February 13, 2026
Verrica Pharmaceuticals Announces Launch of YCANTH® for the Treatment of Molluscum Contagiosum in Japan by Partner Torii Pharmaceutical
February 12, 2026
←
Previous Page
1
2